In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...
Investor's Business Daily on MSN1d
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.
Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...
Immunovant's (NASDAQ:IMVT) stock and Roivant Sciences (ROIV) stock fall after trial data for the former's autoimmune disease ...
The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.
Roivant Sciences Ltd. CEO Matt Cline said the firm’s unit Immunovant Inc. with FcRn blocker batoclimab has established “frankly a new bar” in myasthenia gravis (MG) as the New York-based firm reported ...
Tourlite Capital Management, an investment management firm, released its fourth quarter 2024 investor letter. A copy of the ...
In its fourth quarter 2024 investor letter, Tourlite Capital Management emphasized stocks such as Roivant Sciences Ltd. (NASDAQ:ROIV). Roivant Sciences Ltd. (NASDAQ:ROIV) is a commercial-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback